Please login to the form below
Momenta
This page shows the latest Momenta news and features for those working in and with pharma, biotech and healthcare.
J&J inks $6.5bn all-cash deal to acquire Momenta
J&J will acquire Momenta in an all-cash deal for $52.50 per share, for a total of equity value of $6.5bn. ... The pharma giant also intends to retain Momenta’s presence in Cambridge, Massachusetts to build on the existing innovation capabilities in the
Latest news
-
Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture
Alteogen and Momenta/Mylan have versions of Eylea in development, while Coherus and Xbrane Pharma are among companies which are working on Lucentis biosimilars.
-
Merck confirms sale of biosimilar division
All told, more than a dozen companies, including Amgen, Samsung Bioepis, Boehringer Ingelheim, Momenta Pharmaceuticals and Sandoz, are developing Humira biosimilars, which may be a factor behind Merck's decision to
-
Shire gives up on Momenta-partnered Humira biosimilar
Will fund programme for another 12 months while divesting ongoing activities to Momenta. ... Shire has called time on collaboration with Momenta Pharmaceuticals on the development of a biosimilar version of AbbVie's Humira.
-
Mylan buys into six biosimilars, including Orencia candidate
Deal with Momenta bolsters biosimilars pipeline for new products. Generic pharmaceutical giant Mylan has boosted its position in the emerging biosimilar market via a $245m agreement with Momenta. ... Momenta chief executive Craig Wheeler said the
-
Another setback for Teva's laquinimod in MS
but is now facing generic competition in the US from Sandoz/Momenta's Glatopa.
More from news
Approximately 4 fully matching, plus 15 partially matching documents found.
Latest Intelligence
-
Building a bright future
Mylan’s biosimilar of the multiple sclerosis injection therapy copaxane is not gliding to the promised land, and delays have given rivals Momenta and Novartis’ Sandoz a tilt at the
-
Deal Watch January 2017
625. Momenta. CSL. Licence. M230 immuno-modulator of Fc receptors. 600. ImmuNext.
-
Deal Watch January 2016
255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept).
-
Modern anticoagulants threaten status quo
The LMWH pipeline includes three compounds: certoparin sodium (Embolex; Novartis), semuloparin (Visamerin; Sanofi) and adomiparin (Momenta Pharmaceuticals).
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Voyager Therapeutics appoints Matthew Ottmer as chief operating officer
He joins the gene therapy group from Momenta Pharmaceuticals. Gene therapy focused group Voyager Therapeutics has appointed Matthew Ottmer as its new chief operating officer. ... He joins Voyager most recently from Momenta Pharmaceuticals, where he was
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- Europe’s cancer community publishes new report on transforming patient care
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- EU outlines measures to mitigate antibiotic shortage across Europe
- ASH 2022: bad blood but big advances
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Alzheimer’s Society urges UK government to deliver on dementia plan
- Ipsen reports positive phase 3 data for Onivyde in pancreatic cancer
- Sanofi backs vaccines unit with €350m Canadian facility
- World Health Organization releases latest set of COVID-19 guidelines
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
